FR22C1034I2 - Rapports de médicament fixes pour le traitement des cancers hématopoïétiques et des troubles prolifératifs - Google Patents

Rapports de médicament fixes pour le traitement des cancers hématopoïétiques et des troubles prolifératifs

Info

Publication number
FR22C1034I2
FR22C1034I2 FR22C1034C FR22C1034C FR22C1034I2 FR 22C1034 I2 FR22C1034 I2 FR 22C1034I2 FR 22C1034 C FR22C1034 C FR 22C1034C FR 22C1034 C FR22C1034 C FR 22C1034C FR 22C1034 I2 FR22C1034 I2 FR 22C1034I2
Authority
FR
France
Prior art keywords
treatment
proliferative disorders
hematopoietic cancers
fixed drug
drug ratios
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1034C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rotalec IP Holdings LLC
Original Assignee
Rotalec IP Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1034(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rotalec IP Holdings LLC filed Critical Rotalec IP Holdings LLC
Publication of FR22C1034I1 publication Critical patent/FR22C1034I1/fr
Application granted granted Critical
Publication of FR22C1034I2 publication Critical patent/FR22C1034I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
FR22C1034C 2007-02-16 2022-07-05 Rapports de médicament fixes pour le traitement des cancers hématopoïétiques et des troubles prolifératifs Active FR22C1034I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90177207P 2007-02-16 2007-02-16
US96519607P 2007-08-17 2007-08-17
PCT/US2008/054168 WO2008101214A2 (en) 2007-02-16 2008-02-15 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
EP08730048.9A EP2120568B1 (en) 2007-02-16 2008-02-15 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders

Publications (2)

Publication Number Publication Date
FR22C1034I1 FR22C1034I1 (fr) 2022-09-09
FR22C1034I2 true FR22C1034I2 (fr) 2023-06-30

Family

ID=39690832

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1034C Active FR22C1034I2 (fr) 2007-02-16 2022-07-05 Rapports de médicament fixes pour le traitement des cancers hématopoïétiques et des troubles prolifératifs

Country Status (20)

Country Link
US (2) US8092828B2 (enExample)
EP (3) EP4046640A1 (enExample)
JP (1) JP5314600B2 (enExample)
KR (2) KR20150038752A (enExample)
CN (1) CN105998046A (enExample)
AU (1) AU2008216083B2 (enExample)
CA (1) CA2678332C (enExample)
CY (1) CY1119631T1 (enExample)
DK (2) DK2120568T3 (enExample)
ES (2) ES2909903T3 (enExample)
FR (1) FR22C1034I2 (enExample)
HR (1) HRP20220428T3 (enExample)
HU (2) HUE058334T2 (enExample)
LU (1) LUC00271I2 (enExample)
NL (1) NL301185I2 (enExample)
NO (2) NO2120568T3 (enExample)
PL (2) PL2120568T3 (enExample)
PT (2) PT2120568T (enExample)
SI (1) SI3300601T1 (enExample)
WO (1) WO2008101214A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100075937A1 (en) * 2008-09-24 2010-03-25 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
PT2768484T (pt) 2011-10-21 2019-10-28 Jazz Pharmaceuticals Res Llc Lipossomas liofilizados
US20140154304A1 (en) * 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib
WO2015127172A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015127173A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
BR112018009463A8 (pt) 2015-11-11 2019-02-26 Celator Pharmaceuticals Inc ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
WO2019023873A1 (zh) * 2017-07-31 2019-02-07 江苏竞诺择生物医药科技有限公司 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物
US20240252522A1 (en) * 2018-09-25 2024-08-01 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
TWI744730B (zh) 2018-12-04 2021-11-01 田德揚 用於遞送抗癌劑之立體複合物
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2025088367A1 (en) * 2023-10-27 2025-05-01 Jodas Expoim Pvt. Ltd Liposomal composition of idarubicin and cytarabine and process for preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
BR0316002A (pt) * 2002-11-06 2005-09-13 Celgene Corp Métodos de tratar ou prevenir e controlar uma doença mieloproliferativa, de reduzir ou evitar de um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica e kit
US20040152632A1 (en) 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
WO2004043461A1 (en) * 2002-11-06 2004-05-27 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
JP4972545B2 (ja) * 2004-04-22 2012-07-11 セレーター ファーマスーティカルズ、インク． アントラサイクリン系薬剤及びシチジンアナログのリポソーム製剤
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
US20090148506A1 (en) 2005-12-22 2009-06-11 Awa Dicko Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof

Also Published As

Publication number Publication date
JP5314600B2 (ja) 2013-10-16
ES2909903T3 (es) 2022-05-10
HRP20220428T3 (hr) 2022-05-27
DK2120568T3 (en) 2017-12-11
US8092828B2 (en) 2012-01-10
NO2120568T3 (enExample) 2018-04-14
EP3300601A1 (en) 2018-04-04
WO2008101214A3 (en) 2008-11-20
ES2650167T3 (es) 2018-01-17
PL2120568T3 (pl) 2018-03-30
PT2120568T (pt) 2017-12-04
DK3300601T3 (da) 2022-03-21
AU2008216083B2 (en) 2014-02-06
AU2008216083A2 (en) 2009-09-24
AU2008216083A1 (en) 2008-08-21
CA2678332C (en) 2015-06-02
CN105998046A (zh) 2016-10-12
US20100303895A1 (en) 2010-12-02
SI3300601T1 (sl) 2022-05-31
KR20150038752A (ko) 2015-04-08
JP2010519224A (ja) 2010-06-03
PL3300601T3 (pl) 2022-05-02
CA2678332A1 (en) 2008-08-21
NO2022027I1 (no) 2022-06-30
EP2120568A2 (en) 2009-11-25
HUS2200032I1 (hu) 2022-07-28
CY1119631T1 (el) 2018-04-04
KR20100014441A (ko) 2010-02-10
EP3300601B1 (en) 2022-01-12
EP2120568B1 (en) 2017-11-15
HK1253378A1 (en) 2019-06-14
FR22C1034I1 (fr) 2022-09-09
LUC00271I2 (enExample) 2025-04-25
WO2008101214A2 (en) 2008-08-21
HUE058334T2 (hu) 2022-07-28
PT3300601T (pt) 2022-04-21
US20080199515A1 (en) 2008-08-21
EP2120568A4 (en) 2010-04-21
NL301185I2 (nl) 2022-07-21
EP4046640A1 (en) 2022-08-24

Similar Documents

Publication Publication Date Title
FR22C1034I1 (fr) Rapports de médicament fixes pour le traitement des cancers hématopoïétiques et des troubles prolifératifs
FR20C1061I2 (fr) Anticorps anti-cd38 pour le traitement du cancer
EP2322221A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CANCER
EP2352517A4 (en) METHOD AND COMPOSITIONS FOR TREATING COMPLEMENT ASSOCIATED ILLNESSES
EP2318035A4 (en) METHOD AND COMPOSITIONS FOR TREATING SYMPTOMS OF NEUROLOGICAL AND MENTAL DISORDERS
FR2925339B1 (fr) Medicament pour le traitement du cancer du pancreas
EP2486134A4 (en) USE OF A GREAT LIKE RECEPTOR AND ITS AGENT FOR CANCER TREATMENT
EP1994181A4 (en) IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
EP1985302A4 (en) DRUGS FOR TUMOR THERAPY AND ITS USE
EP2651407A4 (en) 3-METHANSULFONYLPROPIONITRILE FOR THE TREATMENT OF INFLAMMATION AND PAIN
EP2209371A4 (en) COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY
EP2170062A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES
EP2154971A4 (en) SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER
EP2099448A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF RESTENOSIS
EP2273882A4 (en) BIOACTIVE COMPOUNDS FOR THE TREATMENT OF CANCER AND NEURODEEGENERATIVE DISEASES
EP1838320A4 (en) CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL PROBLEMS
EP2593139A4 (en) ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS AND ANTIANGIOGENIC ACTIVITIES FOR THE TREATMENT OF CANCER
EP2194917A4 (en) DEVICES AND METHOD FOR THE TREATMENT OF ADIPOSITAS
EP2349321A4 (en) ANNEXIN AND ITS USE FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP2323641A4 (en) NYASOL AND ANALOGUE THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR-BETA-MEDIATED ILLNESSES
EP2049151A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
FR2929946B1 (fr) Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
EP2034841A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF BIOFILMS
EP2376091A4 (en) NEW TARGETS FOR THE TREATMENT OF HYPERCHOLESTERINMIA
EP2521554A4 (en) MATERIALS AND METHOD FOR PREVENTING AND TREATING VIRUS INFECTIONS